- Previous Close
0.0391 - Open
0.0513 - Bid --
- Ask --
- Day's Range
0.0432 - 0.0432 - 52 Week Range
0.0432 - 0.0432 - Volume
324 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
clene.comRecent News: CLNNW
View MoreCompare To: CLNNW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLNNW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-41.71%
Return on Equity (ttm)
-289.66%
Revenue (ttm)
442k
Net Income Avi to Common (ttm)
-30.46M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
21.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-14.46M